Login / Signup

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®.

Gisle LangsletBernard ZinmanChristoph WannerStefan HantelRosa-Maria EspaderoDavid FitchettOdd Erik Johansen
Published in: Diabetes & vascular disease research (2021)
The beneficial cardiovascular effects of empagliflozin was consistent across higher and lower LDL-cholesterol levels at baseline.
Keyphrases
  • low density lipoprotein